An unmodified strain, HF10, was tested on male Japanese PDAC patients with a 37% efficacy in tumor reduction and no reported side effects, with a positive association to immune activation in patients who received the vector, as demonstrated by increased levels of macrophages, CD4+ and CD8+ cells detected during autopsies (79). The gene discussed is CD8A; the disease is neoplasm.